Efficacy and safety of turmeric 1% emollient cream in the control of chronic kidney disease-associated pruritus in Hemodialysis patients: A randomized double-blind clinical trial
- Author:
Michaela M. Tabalon-Morales
1
;
Karla Phoebe B. Castaños
1
;
Michelle D. Sim
1
Author Information
- Publication Type:Journal Article
- Keywords: Chronic kidney disease-associated pruritus; Uremic pruritus,
- MeSH: Curcuma; Renal Dialysis
- From: Journal of the Philippine Dermatological Society 2022;31(2):14-20
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Chronic kidney disease-associated pruritus (CKD-aP) remains a frequent and distressing symptom in hemodialysis patients, fur-
ther compromising their quality of life. Turmeric, or Curcuma longa, is a naturally-occurring, widely available product that inhibits major inflamma-
tory mechanisms associated with CKD-aP.
Objectives:This study aimed to determine the efficacy and safety of turmeric 1% emollient cream versus a bland emollient in the reduction of chronic kidney disease-associated pruritus in hemodialysis patients.
Methods:This study was a randomized, double-blind, controlled trial of the effect of turmeric 1% cream in the reduction of chronic kidney disease associated pruritus in hemodialysis patients compared to a bland emollient. The main outcome measure was the proportion of subjects who demonstrated response to treatment, as well as the incidence of adverse effects.
Results:Intention to treat analysis on 106 patients, 53 assigned to turmeric 1% cream and 53 to bland emollient cream, was done. There was a sig- nificant difference (P=0.03) in the proportion of patients who achieved treatment success between the turmeric group (66%) and bland emollient group (45%). The mean decrease in pruritus score (VAS) of the group treated with turmeric was significantly greater than that of the bland emol- lient group (P=0.018). No adverse effects were noted in both groups.
Conclusion:Among hemodialysis patients diagnosed with CKD-aP, topical application of turmeric 1% cream twice daily for four weeks was supe- rior to that of bland emollient cream based on efficacy and safety outcome measures. - Full text:03_NOV 2022_TABALON-MORALES.pdf
